3418-22-2

Usage

Uses

Used in Pharmaceutical Industry:
2-(bromomethyl)-2-(4-bromophenyl)-1,3-dioxolane is used as a key intermediate in the synthesis of various drugs and medications. Its unique structure allows for the formation of carbon-carbon bonds, facilitating the creation of complex molecular architectures.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-(bromomethyl)-2-(4-bromophenyl)-1,3-dioxolane serves as a versatile reagent for the development of new compounds with specific properties. Its ability to participate in chemical reactions contributes to the discovery of novel therapeutic agents.
Used in Material Science:
2-(bromomethyl)-2-(4-bromophenyl)-1,3-dioxolane also has potential applications in material science. Its unique chemical structure can be utilized to develop new materials with tailored properties, such as improved stability or specific interactions with other molecules.

Upstream product

• 99-90-1 para-bromoacetophenone 
• 107-21-1 ethylene glycol 
• 5391-88-8 1-(4-bromophenyl)ethanol 
• 99-73-0 para-bromophenacyl bromide 

Downstream Products

• 99-73-0 para-bromophenacyl bromide 
• 71053-90-2 1-{[2-(4-bromophenyl)-1,3-dioxolan-2-yl]methyl}-1H-imidazole hydrochloride 
• 60207-40-1 1-((2-(4-bromophenyl)-1,3-dioxolane-2-yl)methyl)-1H-1,2,4-triazole 

Relevant academic research and scientific papers

Propiconazole-like compound, and preparation method and application thereof

The invention discloses a propiconazole-like compound, and a preparation method and application thereof. The structural formula of the propiconazole-like compound is represented by formula (I)shown in the specification. In the formula (I), X is H, bromine

Application of poly(vinylphenyltrimethylammonium tribromide) resin as an efficient polymeric brominating agent in the α-bromination and α-bromoacetalization of acetophenones

The applications of a new supported tribromide reagent based on poly(vinylbenzyltrimethylammonium hydroxide) resin (Amberlite 717) were reported. This supported tribromide resin was used directly in α-bromination and α-bromoacetalization of acetophenones without any other catalyst under mild conditions. The effects of solvents and the amount of the supported tribromide resin on the reactions were investigated. Under the optimal conditions, most of α-bromo and α-bromoacetal of acetophenones were selectively obtained in excellent yields.

One-pot synthesis of α-bromoacetals of ketones from secondary alcohols and 1,3-dibromo-5,5-dimethylhydantoin (DBDMH) in ethylene glycol

α-Bromoacetals of ketones were prepared from various secondary alcohols with 1,3-dibromo-5,5-dimethylhydantoin (DBDMH) and ethylene glycol through oxidation, bromination, and acetalization in one pot without the use of other catalysts under mild conditions. The effects of DBDMH, the solvent, and N-bromosuccinimide on the reaction were investigated. Under the optimal conditions, most α-bromoacetals of ketones were obtain in 90–98% yields.

One-step for the preparation of α-haloacetal of ketones with N-bromosuccinimide/N-chlorosuccinimide (NBS/NCS) and ethylene glycol

A new process that could directly prepare α-haloacetal of ketones from various ketones with N-halosuccinimide (NBS/NCS) and ethylene glycol in one step without any other catalysts was reported. The effects of solvents, NBS/NCS and reaction temperature were investigated. Under the optimal condition, most of α-haloacetals of ketones were obtained in 90–100% yield.

Heme oxygenase inhibition by 1-Aryl-2-(1H-imidazol-1-yl/1H-1,2,4-triazol-1- yl)ethanones and their derivatives

Previous studies by our research group have been concerned with the design of selective inhibitors of heme oxygenases (HO-1 and HO-2). The majority of these were based on a four-carbon linkage of an azole, usually an imidazole, and an aromatic moiety. In the present study, we designed and synthesized a series of inhibition candidates containing a shorter linkage between these groups, specifically, a series of 1-aryl-2-(1H-imidazol-1-yl/1H-1,2,4-triazol-1-yl) ethanones and their derivatives. As regards HO-1 inhibition, the aromatic moieties yielding best results were found to be halogen-substituted residues such as 3-bromophenyl, 4-bromophenyl, and 3,4-dichlorophenyl, or hydrocarbon residues such as 2-naphthyl, 4-biphenyl, 4-benzylphenyl, and 4-(2-phenethyl)phenyl. Among the imidazole-ketones, five (36-39, and 44) were found to be very potent (IC5050 in favor of HO-1. In the case of the azole-dioxolanes, two of them (80 and 85), each possessing a 2-naphthyl moiety, were found to be particularly potent and selective HO-1 inhibitors. Three non-carbonyl analogues (87, 89, and 91) of 1-(4-chlorophenyl)-2-(1H-imidazol-1-yl)ethanone were found to be good inhibitors of HO-1. For the first time in our studies, two azole-based inhibitors (37 and 39) were found to exhibit a modest selectivity index in favor of HO-2. The present study has revealed additional candidates based on inhibition of heme oxygenases for potentially useful pharmacological and therapeutic applications.